Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Ebiquity's proposed sale of its advertising intelligence business gets the thumbs-up from Numis

The disposal will result in the group becoming a less complex business, focused on higher growth segments
Digital marketing
“This is a transformational moment for Ebiquity,” said CEO Michael Karg

Ebiquity plc (LON:EBQ) is to sell its advertising intelligence (AdIntel) business to Nielsen Holdings PLC for £26mln in cash.

Ebiquity said the disposal would increase its focus on its Media Value Measurement (MVM) and Marketing Performance Optimisation (MPO) divisions, which historically have shown faster rates of growth than the Market Intelligence (MI) division.

The consideration, which is subject to adjustments for working capital, will substantially reduce the group’s debt position from 2.1 times annual underlying earnings (EBITDA) as at the end of 2017 to a level roughly equivalent to annual EBITDA on a pro forma basis.

The AdIntel business represents more than 90% of the group’s Market Intelligence (MI) division, and its disposal will result in the group becoming a more focused and less complex business. It will also provide the firepower to invest in proprietary technology and data analytics capabilities across the remainder of the business.

“This is a transformational moment for Ebiquity,” said Michael Karg, the chief executive officer of Ebiquity.

“Our Growth Acceleration Plan, which focuses on seizing market opportunities in our faster growing MVM and MPO segments, will be enhanced through our ability to invest in these services to seize and establish a leadership position. Nielsen is the logical home for our colleagues in MI and we wish them every success for the future," he added.

Pre-close trading statement for 2017

As well as announcing the disposal, Ebiquity released a pre-close trading statement for 2017.

Revenues grew 4.9%, or 1.5% on a constant currency (CC) basis, to £87.6mln. Stripping out the Market Intelligence – most of which is the soon to be disposed of AdIntel business – revenue growth was 7.0% or 3.3% on a CC basis.

As expected, revenue growth was faster in the second half of the year than in the first; CC revenue growth in the second half of the year (excluding the MI division) was 7.3% year-on-year.

READ: Ebiquity expects momentum to continue in second half

As previously indicated, the revenue performance in the US from the MVM and MPO businesses was below expectations, which diluted the group’s growth.

Excluding US revenues, the MVM and MPO practices grew by 10.5% and 10.9% respectively on a constant currency basis.

New leadership is now in place for the US business units in order to facilitate a sustained turnaround with the appointment of a US-based global chief operating officer. 

Numis Securities said the disposal price was slightly above its own valuation of the AdIntel business.

More pertinently, it regards the strategic rationale for the sale as “compelling”, as it enables the group to focus on its faster-growing, higher-margin technology-enabled consultancy practices while materially reducing debt.

News that the previously flagged problems with the US divisions continued into the second half prompted the broker to cut its full-year profit before tax and earnings per share forecasts to £10.8mln and 9.7p respectively, from £12.0mln and 10.5p previously.

Forecasts for fiscal 2018 were lowered to £10.2mln and 8.8p from £11.3mln and 9.4p previously, although obviously the sale of AdIntel – if it goes through – will have an impact on those numbers.

Numis indicated that on a pro forma basis its 2018 profit before tax forecast would move to £7.0mln and its earnings per share estimate to 5.9p.

“Although initially dilutive, in our view the disposal provides a platform for the group to generate sector-leading growth which can be supported by focussed investment,” Numis said, as it stuck with its ‘buy’ recommendation and 145p target price.

Shares in Ebiquity were down half a penny at 100p.

--- adds broker comment and share price ---

View full EBQ profile View Profile

Ebiquity plc Timeline

Big Picture
February 13 2018

Related Articles

April 16 2018
Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006
Marketing and public relations
April 04 2018
"Our Beyond, MBooth and Publitek agencies have been stand-out performers, whilst we have achieved solid performances pretty much across the portfolio"
Lego ball
September 14 2018
The company's latest push is a joint venture agreement with US-based entertainment firm Three Six Zero, which has steered the careers of pop stars such as Calvin Harris

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use